







What is Crimean-Congo hemorrhagic fever? 
Crimean-Congo hemorrhagic fever (CCHF) is caused by infection with 
a tick-borne virus (Nairovirus) in the family Bunyaviridae.  The disease 
was first characterized in the Crimea in 1944 and given the name 
Crimean hemorrhagic fever.  It was then later recognized in 1969 as 
the cause of illness in the Congo, thus resulting in the current name of 
the disease.   
 
 
Where is the disease found? 
Crimean-Congo hemorrhagic fever is found in Eastern Europe, 
particularly in the former Soviet Union.  It is also distributed throughout 
the Mediterranean, in northwestern China, central Asia, southern 
Europe, Africa, the Middle East, and the Indian subcontinent. 
 
 
How is CCHF spread and how do humans become infected?  
Hyalomma tick image. 
Ixodid (hard) ticks, especially those of the genus, Hyalomma, are both 
a reservoir and a vector for the CCHF virus.  Numerous wild and 
domestic animals, such as cattle, goats, sheep and hares, serve as 
amplifying hosts for the virus. Transmission to humans occurs through 
contact with infected animal blood or ticks.  CCHF can be transmitted 
from one infected human to another by contact with infectious blood or 
body fluids.  Documented spread of CCHF has also occurred in hospitals due to improper sterilization of 
medical equipment, reuse of injection needles, and contamination of medical supplies.   
 
 
What are the symptoms of Crimean-Congo hemorrhagic fever? 
The onset of CCHF is sudden, with initial signs and symptoms including headache, high fever, back pain, joint 
pain, stomach pain, and vomiting.  Red eyes, a flushed face, a red throat, and petechiae (red spots) on the 
palate are common. Symptoms may also include jaundice, and in severe cases, changes in mood and sensory 
perception.  As the illness progresses, large areas of severe bruising, severe nosebleeds, and uncontrolled 




How is Crimean-Congo hemorrhagic fever diagnosed? 
Laboratory diagnosis of CCHF can be made by finding a positive serological test result, evidence of viral 
antigen in tissue by immunohistochemical staining and microscopic examination, or identification of viral RNA 




Are there complications after recovery? 
The long-term effects of CCHF infection have not been studied well enough in survivors to determine whether 
or not specific complications exist.  However, recovery is slow.   
 
 
Is the disease ever fatal? 




How is Crimean-Congo hemorrhagic fever treated? 
Treatment for CCHF is primarily supportive.  Care should include careful attention to fluid balance and 
correction of electrolyte abnormalities, oxygenation and hemodynamic support, and appropriate treatment of 
secondary infections.  The virus is sensitive in vitro to the antiviral drug ribavirin.  It has been used in the 
treatment of CCHF patients reportedly with some benefit.   
 
 
Who is at risk for the disease? 
Animal herders, livestock workers, and slaughter houses in endemic areas are at risk of CCHF.  Healthcare 
workers in endemic areas are at risk of infection through unprotected contact with infectious blood and body 




How is the disease prevented? 
Agricultural workers and others working with animals should use insect repellent on exposed skin and clothing.  
Insect repellants containing DEET (N, N-diethyl-m-toluamide) are the most effective in warding off ticks.  
Wearing gloves and other protective clothing is recommended.  Individuals should also avoid contact with the 
blood and body fluids of livestock or humans who show symptoms of infection.  It is important for healthcare 
workers to use proper infection control precautions to prevent occupational exposure.  
 
An inactivated, mouse-brain derived vaccine against CCHF has been developed and is used on a small scale 
in Eastern Europe.  However, there is no safe and effective vaccine widely available for human use. 
 
 
What needs to be done to address the threat of Crimean-Congo hemorrhagic fever? 
Prevalence needs to be measured in animals and in at-risk humans in endemic areas; and a useful animal 
model needs to be developed.  Further research is needed to determine the efficacy of specific treatment with 
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